error
Divisa

PEDIATRIC ONCOLOGIC PHARMACY

A COMPLETE GUIDE TO PRACTICE

9783030109875 ::  PEDIATRIC ONCOLOGIC PHARMACY
ISBN:

9783030109875

EditorialSPRINGER NATURE
Edicion:
Idioma:INGLES
P.V.P.: 89,99 € + 4% IVA = 93,59 €
Dto 5% Ahorras 4,68 €
Importe final iva incl. 88,91 €
PLAZO DE ENTREGA 15 DIAS

THERE ARE FEW PUBLICATIONS ABOUT CHEMOTHERAPY IN CHILDREN, AND NONE OF THEM IS A BOOK AIMED AT PHARMACISTS. PEDIATRIC ONCOLOGY PHARMACY IS AN AREA WHERE MORE AND MORE SPECIFIC KNOWLEDGE IS REQUIRED IN DAILY PRACTICE. PHARMACISTS WHO WORK IN PEDIATRIC ONCOLOGY AREA DO NOT HAVE A BOOK DIRECTED AT THEM; NONE OF THE ONCOPEDIATRIC BOOKS ADDRESSES TOPICS UNIQUE TO PHARMACY — SUCH AS MANIPULATION OF CYTOTOXIC DRUGS FOR CHILDREN, ANALYSIS OF ONCOPEDIATRIC PRESCRIPTIONS, CLINICAL PHARMACY IN ONCOPEDIATRICS, PHARMACEUTICAL CARE IN ONCOPEDIATRIC AREA, AND OTHER SUBJECTS THAT ARE OF EXCLUSIVE INTEREST TO THESE PROFESSIONALS, BUT NO LESS ESSENTIAL FOR A THERAPY OF EXCELLENCE. AS FOR THIS NEED, THE PURPOSE OF THIS BOOK IS TO BE A GUIDELINE FOR ALL SUBJECTS THAT PEDIATRIC ONCOLOGY PHARMACISTS NEED TO KNOW TO WORK IN THIS AREA. IT WILL BE AN ESSENTIAL GUIDE TO PEDIATRIC ONCOLOGY PHARMACISTS, CLINICAL PHARMACISTS, PHARMACEUTICAL RESIDENTS WHO WORK WITH DRUG THERAPY IN CHILDREN AND PHARMACEUTICAL RESEARCHERS. IT WILL BE A POCKET GUIDE TO ASSIST IN DAILY PRACTICE, AND IT WILL BE ESSENTIAL TO PEDIATRIC ONCOLOGY/ HEMATOLOGY INSTITUTIONS. THE ESSENTIAL PROPOSE OF THIS BOOK IS TO BE THE FIRST ONE FOCUSING PEDIATRIC ONCOLOGY FOR PHARMACISTS.

<B>1.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; </B>INTRODUCTION<P>1.1&NBSP;&NBSP; THE PHARMACIST AND CHEMOTHERAPY IN CHILDREN</P>1.2&NBSP;&NBSP; PHARMACIST IN PEDIATRIC HEMATO/ ONCOLOGICAL AREA<P></P><P>1.3&NBSP;&NBSP; PHARMACIST IN RHEUMATOLOGY AREA: CHEMOTHERAPY FOR RHEUMATIC CHILDREN</P><P>1.4&NBSP;&NBSP; DIFFERENCES IN SECTORS OF MANIPULATION OF CHEMOTHERAPY AROUND THE WORLD</P><P>1.5&NBSP;&NBSP; CHEMOTHERAPY IN CHILDREN</P><P>1.6&NBSP;&NBSP; CHEMOTHERAPY IN NEONATES AND INFANTS</P><P>&NBSP;</P><P><B>2.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; </B><B>DISEASES IN PEDIATRIC HEMATO/ ONCOLOGY AREA AND TREATMENTS</B></P><P>2.1&NBSP;&NBSP; ACUTE LYMPHOID LEUKEMIA</P><P>2.2&NBSP;&NBSP; ACUTE MYELOID LEUKEMIA</P><P>2.3&NBSP;&NBSP; CHRONIC MYELOID LEUKEMIA</P><P>2.4&NBSP;&NBSP; HODGKIN LYMPHOMA</P><P>2.5&NBSP;&NBSP; NON-HODGKIN LYMPHOMA</P><P>2.6&NBSP;&NBSP; OSTEOSARCOMA</P><P>2.7&NBSP;&NBSP; CENTRAL NERVOUS SYSTEM TUMORS</P><P>2.8&NBSP;&NBSP; RETINOBLASTOMA</P><P>2.9&NBSP;&NBSP; WILMS TUMOR</P><P>2.10 BURKITT’S LYMPHOMA</P><P>2.11 HEPATOBLASTOMA</P><P>2.12 CONGENITAL TUMORS </P><P>&NBSP;</P><P><B>3.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; </B>DISEASES IN RHEUMATOLOGY AND THEIR TREATMENT WITH CHEMOTHERAPY</P><P>3.1&NBSP;&NBSP; SOMETIMES SYMPTOMS OF RHEUMATIC DISEASES IS, ACTUALLY, FIRST SIGN OF PEDIATRIC CANCER</P><P>3.2&NBSP;&NBSP; RHEUMATIC DISEASE IN CHILDREN</P><P>3.3&NBSP;&NBSP; INTRODUCTION</P><P> 3.3.1 PEDIATRIC LUPUS</P><P> 3.3.2 PEDIATRIC IDIOPATHIC ARTHRITIS</P><P> 3.3.3 PEDIATRIC DERMATOMYOSITIS</P><P> 3.3.4 PEDIATRIC&NBSP; SCLERODERMA</P><P> 3.3.5 PEDIATRIC KAWASAKI DISEASE</P><P> 3.3.6 PEDIATRIC MIXED CONNECTIVE TISSUE DISEASE</P><P> 3.3.7 PEDIATRIC FIBROMYALGIA</P><P> 3.3.8 RHEUMATIC DISEASES IN NEONATES AND INFANTS</P><P><B>&NBSP;</B><BR></P><P>4.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; <B>PHARMACOKINETICS AND PHARMACODYNAMICS OF CHEMOTHERAPY IN CHILDREN — THE USED DRUGS</B></P><P>4.1&NBSP;&NBSP; BRENTUXIMAB</P><P>4.2&NBSP;&NBSP; BUSULFAN</P><P>4.3&NBSP;&NBSP; CARBOPLATIN</P><P>4.4&NBSP;&NBSP; CARMUSTINE</P><P>4.5&NBSP;&NBSP; CISPLATIN</P><P>4.6&NBSP;&NBSP; CYCLOPHOSPHAMIDE</P><P>4.7&NBSP;&NBSP; CYTARABINE</P><P>4.8&NBSP;&NBSP; DACARBAZINE</P><P>4.9&NBSP;&NBSP; DAUNORUBICIN</P><P>4.10&NBSP;&NBSP;&NBSP; DOCETAXEL</P><P>4.11&NBSP;&NBSP;&NBSP; DOXORUBICIN</P><P>4.12&NBSP;&NBSP;&NBSP; ETOPOSIDE</P><P>4.13&NBSP;&NBSP;&NBSP; GENTAMICIN</P><P>4.14&NBSP;&NBSP;&NBSP; HYDROXYUREA</P><P>4.15&NBSP;&NBSP;&NBSP; IDARUBICIN</P><P>4.16&NBSP;&NBSP;&NBSP; IFOSFAMIDE</P><P>4.17&NBSP;&NBSP;&NBSP; IMATINIB</P><P>4.18&NBSP;&NBSP;&NBSP; IRINOTECAN</P><P>4.19&NBSP;&NBSP;&NBSP; LOMUSTINE</P><P>4.20&NBSP;&NBSP;&NBSP; L-ASPARAGINASE</P><P>4.21&NBSP;&NBSP;&NBSP; METHOTREXATE</P><P>4.22&NBSP;&NBSP;&NBSP; PACLITAXEL</P><P>4.23&NBSP;&NBSP;&NBSP; TRANS RETINOIC ACID</P><P>4.24&NBSP;&NBSP;&NBSP; VINBLASTINE</P><P>4.25&NBSP;&NBSP;&NBSP; VINCRISTINE</P><P>4.26&NBSP;&NBSP;&NBSP; VINORELBINE</P><P><B>&NBSP;</B></P><P><B>5.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; </B><B>PHYSICAL-CHEMICAL COMPATIBILITY OF DRUGS USED IN CHEMOTHERAPY FOR CHILDREN</B><B></B></P><P>5.1&NBSP;&NBSP; BRENTUXIMAB</P><P>5.2&NBSP;&NBSP; BUSULFAN</P><P>5.3&NBSP;&NBSP; CARBOPLATIN</P><P>5.4&NBSP;&NBSP; CARMUSTINE</P><P>5.5&NBSP;&NBSP; CISPLATIN</P><P>5.6&NBSP;&NBSP; CYCLOPHOSPHAMIDE</P><P>5.7&NBSP;&NBSP; CYTARABINE</P><P>5.8&NBSP;&NBSP; DACARBAZINE</P><P>5.9&NBSP;&NBSP; DAUNORUBICIN</P><P>5.10&NBSP;&NBSP;&NBSP; DOCETAXEL</P><P>5.11&NBSP;&NBSP;&NBSP; DOXORUBICIN</P><P>5.12&NBSP;&NBSP;&NBSP; ETOPOSIDE</P><P>5.13&NBSP;&NBSP;&NBSP; GENTAMICIN</P><P>5.14&NBSP;&NBSP;&NBSP; IDARUBICIN</P><P>5.15&NBSP;&NBSP;&NBSP; IFOSFAMIDE</P><P>5.16&NBSP;&NBSP;&NBSP; IRINOTECAN</P><P>5.17&NBSP;&NBSP;&NBSP; LOMUSTINE</P><P>5.18&NBSP;&NBSP;&NBSP; L-ASPARAGINASE</P><P>5.19&NBSP;&NBSP;&NBSP; METHOTREXATE</P><P>5.20&NBSP;&NBSP;&NBSP; PACLITAXEL</P><P>5.21&NBSP;&NBSP;&NBSP; VINBLASTINE</P><P>5.22&NBSP;&NBSP;&NBSP; VINCRISTINE</P><P>5.23&NBSP;&NBSP;&NBSP; VINORELBINE</P><P><B>&NBSP;</B><B>&NBSP;</B></P><P>6.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; <B>DRUG INTERACTIONS INVOLVING CHEMOTHERAPY FOR CHILDREN</B></P><P><B>&NBSP;</B>(THIS CHAPTER WILL PROVIDE TABLES WITH VERY PRACTICAL INFORMATION OF DRUG INTERACTIONS, RESUMED MECHANISM OF EACH INTERACTION AND, IN CASE OF UNDESIRABLE INTERACTIONS, ALTERNATIVES TO AVOID THEM).</P><P><B>&NBSP;</B></P><P>7.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; <B>PRESCRIPTION ANALYSIS</B></P><P>&NBSP;(THIS CHAPTER WILL PROVIDE INFORMATION ABOUT PRESCRIPTION ANALYSIS OF PROTOCOLS, DOSES, PHYSICAL-CHEMICAL COMPATIBILITIES, DRUG INTERACTIONS, PATIENTS FOLLOW-UP, LABORATORY TESTS AND OTHER PERTINENT SUBJECTS).&NBSP;</P><P><B>&NBSP;</B></P><P><B>8.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; </B><B>HANDLING PEDIATRIC CHEMOTHERAPY</B></P><P>8.1&NBSP;&NBSP; INTRAVENOUS</P> 8.2&NBSP;&NBSP; INTRAMUSCULAR<P></P><P> 8.3&NBSP;&NBSP; SUBCUTANEOUS</P><P> 8.4&NBSP;&NBSP; FOR USE IN SURGERY</P><P>&NBSP;</P><P><B>9.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; </B>HANDLING PEDIATRIC INTRATHECAL DRUGS</P><P>(THIS IS A VERY IMPORTANT TOPIC, GIVEN THAT INTRATHECAL CHEMOTHERAPY IS LARGELY USED IN PEDIATRICS AND IT HAS MANY PECULIARITIES). </P><P>&NBSP;</P><P><B>10.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; </B><B>HANDLING PEDIATRIC EXTEMPORANEOUS ORAL SOLUTIONS WITH CHEMOTHERAPY</B></P><P><B>&NBSP;</B>(THIS IS A VERY IMPORTANT TOPIC AIMED TO PEDIATRIC ONCOLOGY. SOMETIMES PATIENTS ARE NEONATES, INFANTS OR SIMPLY CANNOT SWALLOW. THIS CHAPTER WILL PROVIDE PHARMACOTECHNICAL COMPLETE INFORMATION TO CONVERT TABLETS INTO SYRUP, AS SHELF LIFE, HOW TO PREPARE EACH DRUG AND OTHER IMPORTANT SUBJECTS).&NBSP;</P><P><B>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; </B></P><P><B>11.&NBSP;&NBSP; </B><B>ADMINISTRATION OF A PEDIATRIC ONCOLOGY PHARMACY: FROM THE PURCHASE OF THE DRUGS TO THE DISPENSATION</B></P><P>(ALL ADMINISTRATION SUBJECTS THAT PHARMACISTS NEED TO KNOW TO WORK IN A PEDIATRIC ONCOLOGY PHARMACY, AS SELECTIVE INVENTORY&NBSP;CONTROL/ ABC CURVE, CURVE XYZ, SELECTION OF SUPPLIERS, LOT TRACKING, TRACEABILITY, RECEIVING DRUGS, COMPUTERIZED SYSTEM AND REPORTS).&NBSP;</P><P>&NBSP;</P><P><B>12.&NBSP;&NBSP; </B>CHEMOTHERAPY FOR PEDIATRIC STEM CELL TRANSPLANTATION</P><P>&NBSP;(PHARMACISTS EVEN MORE HANDLE CHEMOTHERAPY FOR STEM CELL TRANSPLANTATION IN CHILDREN. CHEMOTHERAPY FOR STEM CELL TRANSPLANTATION VARIES A LOT FROM THAT USED FOR CANCER AND TUMORS TREATMENT. THIS CHAPTER WILL PROVIDE ALL INFORMATION NEEDED FOR A SAFETY HANDLING OF THESE DRUGS FOR STEM CELL TRANSPLANTATION).</P><P>&NBSP;</P><P><B>13.&NBSP;&NBSP; </B>BIOSAFETY FOR PHARMACISTS AND TECHNICAL TEAM IN PEDIATRIC CHEMOTHERAPY AREA</P><P><B>&NBSP;</B>(THIS CHAPTER WILL PROVIDE INFORMATION ABOUT SAFETY FOR PHARMACISTS, APPROPRIATE EQUIPMENT, NECESSARY EXAMINATIONS, RISKS AND OTHER PERTINENT SUBJECTS).</P><P><B>&NBSP;</B></P><P><B>14.&NBSP;&NBSP; </B><B>SUPPORTIVE THERAPY FOR PEDIATRIC PATIENTS RECEIVING TREATMENT WITH CHEMOTHERAPY</B><B></B></P><P>14.1&NBSP;&NBSP;PEDIATRIC PAIN AND THE PHARMACIST</P><P>14.2&NBSP;&NBSP;&NBSP;&NBSP;PEDIATRIC NAUSEA AND VOMITING AND THE PHARMACIST</P>14.3&NBSP; &NBSP;&NBSP;PEDIATRIC INFECTIOUS DISEASES DURING CHEMOTHERAPY TREATMENT AND THE PHARMACIST<P></P><P><B>&NBSP;</B></P><P><B>15.&NBSP;&NBSP; </B><B>PEDIATRIC CLINICAL PHARMACY INVOLVING CHEMOTHERAPY</B></P><P><B>&NBSP;</B></P><P><B>16.&NBSP;&NBSP; </B><B>PEDIATRIC PHARMACEUTICAL CARE INVOLVING CHEMOTHERAPY</B></P><P><B>&NBSP;</B></P><P><B>17.&NBSP;&NBSP;</B> <B>APPENDIX</B></P><P>17.1&NBSP;BODY SURFACE AREA</P><P> 17.2&NBSP;TUMOR LYSIS SYNDROME</P><P><B>&NBSP;</B></P><P><B>18.&NBSP;</B>&NBSP; <B>REFERENCES</B></P><P><BR></P>

PEDIATRIA
Libros relacionados
ISBN: 9783030212667 PEDIATRIC BOARD STUDY GUIDEPEDIATRIC BOARD STUDY GUIDE
9783030212667
Noviembre 2019

64.99€ S/I
61,74€ S/I

ISBN: 9783030262792 PEDIATRIC AUTOIMMUNITY AND TRANSPLANTATIONPEDIATRIC AUTOIMMUNITY AND ...
9783030262792
Noviembre 2019

119.99€ S/I
113,99€ S/I

ISBN: 9783662589441 PALLIATIVVERSORGUNG UND TRAUERBEGLEITUNG IN DER NEONATOLOGIEPALLIATIVVERSORGUNG UND ...
9783662589441
Noviembre 2019

37.37€ S/I
35,50€ S/I

ISBN: 9789811378638 DISORDERS|DIFFERENCES OF SEX DEVELOPMENTDISORDERS|DIFFERENCES OF SEX DEVELOPMENT
9789811378638
Noviembre 2019

129.99€ S/I
123,49€ S/I

ISBN: 9783030212612 PEDIATRIC IMMUNOLOGYPEDIATRIC IMMUNOLOGY
9783030212612
Octubre 2019

129.99€ S/I
123,49€ S/I